LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

30.73 3.47

Overview

Share price change

24h

Current

Min

30.18

Max

30.79

Key metrics

By Trading Economics

Income

-19M

-116M

Sales

670K

1M

Profit margin

-11,216.004

Employees

437

EBITDA

-19M

-129M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+120.54% upside

Dividends

By Dow Jones

Next Earnings

11 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-65M

2.6B

Previous open

27.26

Previous close

30.73

News Sentiment

By Acuity

50%

50%

157 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 Aug 2025, 16:11 UTC

Major Market Movers

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15 Aug 2025, 22:22 UTC

Market Talk

Global Equities Roundup: Market Talk

15 Aug 2025, 22:22 UTC

Market Talk

Target Is Falling Behind Its Peers -- Market Talk

15 Aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 Aug 2025, 20:33 UTC

Market Talk

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15 Aug 2025, 20:25 UTC

Earnings
Acquisitions, Mergers, Takeovers

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15 Aug 2025, 20:24 UTC

Earnings
Acquisitions, Mergers, Takeovers

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 Aug 2025, 20:18 UTC

Earnings

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 Aug 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15 Aug 2025, 19:12 UTC

Market Talk

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15 Aug 2025, 18:32 UTC

Market Talk

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15 Aug 2025, 17:33 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15 Aug 2025, 17:23 UTC

Market Talk
Earnings

Deere's Earnings Appear to Be Troughing -- Market Talk

15 Aug 2025, 16:27 UTC

Earnings

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15 Aug 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 Aug 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 Aug 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 Aug 2025, 16:05 UTC

Acquisitions, Mergers, Takeovers

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15 Aug 2025, 15:52 UTC

Acquisitions, Mergers, Takeovers

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15 Aug 2025, 15:36 UTC

Market Talk

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15 Aug 2025, 15:29 UTC

Earnings

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 Aug 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 Aug 2025, 15:28 UTC

Earnings

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15 Aug 2025, 15:24 UTC

Market Talk

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15 Aug 2025, 15:08 UTC

Market Talk

Applied Materials Is Losing Share in Chips Business -- Market Talk

15 Aug 2025, 14:38 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15 Aug 2025, 14:37 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15 Aug 2025, 14:37 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15 Aug 2025, 14:36 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15 Aug 2025, 14:33 UTC

Acquisitions, Mergers, Takeovers

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

120.54% upside

12 Months Forecast

Average 67.75 USD  120.54%

High 97 USD

Low 31 USD

Based on 13 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

157 / 374 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.